ME01205B - Upotreba soli tiotropijuma u liječenju umjerene trajne astme - Google Patents
Upotreba soli tiotropijuma u liječenju umjerene trajne astmeInfo
- Publication number
- ME01205B ME01205B MEP-2011-62A MEP6211A ME01205B ME 01205 B ME01205 B ME 01205B ME P6211 A MEP6211 A ME P6211A ME 01205 B ME01205 B ME 01205B
- Authority
- ME
- Montenegro
- Prior art keywords
- treatment
- drug
- production
- asthma
- patients
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims 10
- 230000002085 persistent effect Effects 0.000 title claims 8
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title claims 3
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 4
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 3
- 101150033809 ADRB2 gene Proteins 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 210000000349 chromosome Anatomy 0.000 claims 2
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000009115 maintenance therapy Methods 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (8)
1. Upotreba soli tiotropijuma 1 gde X- označava anjon sa jednim negativnim naelektrisanjem, prvenstveno anjon koji je odabran između hlorida, bromida, jedida, sulfata, fosfata, metansulfonata, nitrata, maleata, acetata, citrata, fumarata, tartrata, oksalata, sukcinata, benzoata i p-toluolsulfonata, opcionalno u obliku njihovih hidrata i/ili solvata, za proizvodnju leka za lečenje astme trećeg stepena težine prema GlNA smernicama.
2.Upotreba, prema zahtevu 1, za proizvodnju leka za lečenje umerene trajne astme kod pacijenata koji imaju dnevne simptome uprkos lečenju inhalacionim kortikosteroidima.
3.Upotreba, prema zahtevu 1 ili 2, za proizvodnju leka za lečenje umerene trajne astme kod pacijenata koji imaju trajne simptome, uprkos lečnju inhalacionim beta-2-agonistima, kod pacijenata koji nose Arg/Arg genotip na kodonu 16 ADRB2 gena (hromozom 5).
4.Upotreba, prema jednom od zahteva 1 ili 2, za proizvodnju leka za lečenje umerene trajne astme kod pacijenata koji nose Arg/Arg genotip na kodonu 16 ADRB2 gena (hromozom 5), a koji imaju dnevne simptome, uprkos lečenju inhalacionim kortikosteroidima kombinovanim sa dugo-delujućim beta-2- agonistima. •
5.Upotreba, prema jednom od zahteva od 1 do 4, za proizvodnju leka za lečenje umerene trajne astme gde su pacijenti deca.
6.Upotreba, prema jednom od zahteva od 1 do 5, za proizvodnju leka koji se koristi u terapiji za održavanje umerene trajne astme i prevenciju bronho opstruktivnih simptoma kod pacijenata kod kojih astma nije adekvatno kontrolisana terapijom za održavanje astme inhalacionim kortikosteroidima i dugodelujućim beta-2-agonistima.
7.Upotreba, prema jednom od zahteva od 1 do 6, za proizvodnju leka koji se koristi kao kontrolna terapija trećeg reda za održavanje umerene trajne astme.
8.Upotreba, prema jednom od zahteva od 1 do 7, gde je poželjno po svakoj pojedinačnoj dozi primenjivati 1-20 µg tiotropijuma 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06100055 | 2006-01-04 | ||
| PCT/EP2006/070135 WO2007077162A1 (en) | 2006-01-04 | 2006-12-22 | Use of tiotropium salts in the treatment of moderate persistent asthma |
| EP06830792A EP1971332B1 (en) | 2006-01-04 | 2006-12-22 | Use of tiotropium salts in the treatment of moderate persistent asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01205B true ME01205B (me) | 2013-03-20 |
Family
ID=35695896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-62A ME01205B (me) | 2006-01-04 | 2006-12-22 | Upotreba soli tiotropijuma u liječenju umjerene trajne astme |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20070155773A1 (me) |
| EP (1) | EP1971332B1 (me) |
| JP (1) | JP2009525950A (me) |
| KR (1) | KR20080083060A (me) |
| CN (1) | CN101355937A (me) |
| AR (1) | AR059126A1 (me) |
| AT (1) | ATE500825T1 (me) |
| AU (1) | AU2006334367B2 (me) |
| BR (1) | BRPI0620886A2 (me) |
| CA (1) | CA2634984C (me) |
| CY (1) | CY1111534T1 (me) |
| DE (1) | DE602006020620D1 (me) |
| DK (1) | DK1971332T3 (me) |
| EA (1) | EA015353B1 (me) |
| EC (1) | ECSP088588A (me) |
| ES (1) | ES2362306T3 (me) |
| HR (1) | HRP20110200T1 (me) |
| IL (1) | IL192602A (me) |
| ME (1) | ME01205B (me) |
| MY (1) | MY146362A (me) |
| NO (1) | NO20082439L (me) |
| NZ (1) | NZ570162A (me) |
| PL (1) | PL1971332T3 (me) |
| PT (1) | PT1971332E (me) |
| RS (1) | RS51703B (me) |
| SI (1) | SI1971332T1 (me) |
| TW (1) | TW200731976A (me) |
| UA (1) | UA95271C2 (me) |
| WO (1) | WO2007077162A1 (me) |
| ZA (1) | ZA200804436B (me) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006277968A1 (en) | 2005-08-06 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Use of tiotropium salts in the treatment of severe persistant asthma |
| WO2015065222A1 (ru) * | 2013-10-28 | 2015-05-07 | Шолекс Девелопмент Гмбх | Фармацевтический ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких, содержащий в качестве активного вещества микронизированный тиотропия бромид, и способ его получения |
| GB201321717D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| CN110876720A (zh) * | 2018-09-06 | 2020-03-13 | 天津金耀集团有限公司 | 依地酸盐恰当改变噻托溴铵喷雾剂表面张力的应用 |
| CN110876721A (zh) * | 2018-09-06 | 2020-03-13 | 天津金耀集团有限公司 | 一种含有表面活性剂的噻托溴铵喷雾剂 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2425539A (en) * | 1942-10-31 | 1947-08-12 | Aro Equipment Corp | Coupling |
| DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US5610163A (en) * | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| US6156503A (en) * | 1997-03-03 | 2000-12-05 | The Regents Of The University Of California | Diagnosing asthma patients predisposed to adverse β-agonist reactions |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| CN100519558C (zh) * | 2000-10-12 | 2009-07-29 | 贝林格尔英格海姆法玛两合公司 | 结晶单水合物、其制备方法及其在制备药物组合中的用途 |
| US6908928B2 (en) * | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| US6608055B2 (en) * | 2001-06-22 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
| US6919325B2 (en) * | 2001-09-14 | 2005-07-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts |
| US7951557B2 (en) * | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| US7968717B2 (en) * | 2003-11-03 | 2011-06-28 | Boehringer Ingelhein International Gmbh | Crystalline anhydrate with anticholinergic efficacy |
| MXPA06004697A (es) * | 2003-11-03 | 2006-07-05 | Boehringer Ingelheim Int | Procedimiento para la preparacion de sales de tiotropio, sles de tiotropio, asi como formulaciones medicamentosas que las contienen. |
| ES2338563T3 (es) * | 2003-11-03 | 2010-05-10 | Boehringer Ingelheim International Gmbh | Nuevo anhidrato cristalino con efecto anticolinergico. |
| SE0303571D0 (sv) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive medicaments |
| SE0303570L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
| US20060269946A1 (en) * | 2005-05-10 | 2006-11-30 | Young Robert P | Methods and compositions for assessment of pulmonary function and disorders |
| EP1888779A4 (en) * | 2005-05-20 | 2009-06-10 | Synergenz Bioscience Ltd | METHOD FOR THE ANALYSIS OF POLYMORPHISMS AND USES THEREOF |
| AU2006277968A1 (en) * | 2005-08-06 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Use of tiotropium salts in the treatment of severe persistant asthma |
| US20070167480A1 (en) * | 2005-12-19 | 2007-07-19 | Sicor Inc. | Pure and stable tiotropium bromide |
-
2006
- 2006-12-22 JP JP2008548980A patent/JP2009525950A/ja active Pending
- 2006-12-22 PL PL06830792T patent/PL1971332T3/pl unknown
- 2006-12-22 UA UAA200809746A patent/UA95271C2/ru unknown
- 2006-12-22 RS RS20110147A patent/RS51703B/sr unknown
- 2006-12-22 ES ES06830792T patent/ES2362306T3/es active Active
- 2006-12-22 ME MEP-2011-62A patent/ME01205B/me unknown
- 2006-12-22 EA EA200801629A patent/EA015353B1/ru not_active IP Right Cessation
- 2006-12-22 HR HR20110200T patent/HRP20110200T1/hr unknown
- 2006-12-22 SI SI200630986T patent/SI1971332T1/sl unknown
- 2006-12-22 BR BRPI0620886-0A patent/BRPI0620886A2/pt not_active Application Discontinuation
- 2006-12-22 AU AU2006334367A patent/AU2006334367B2/en active Active
- 2006-12-22 AT AT06830792T patent/ATE500825T1/de active
- 2006-12-22 DE DE602006020620T patent/DE602006020620D1/de active Active
- 2006-12-22 CA CA2634984A patent/CA2634984C/en not_active Expired - Fee Related
- 2006-12-22 PT PT06830792T patent/PT1971332E/pt unknown
- 2006-12-22 CN CNA2006800504685A patent/CN101355937A/zh active Pending
- 2006-12-22 EP EP06830792A patent/EP1971332B1/en not_active Revoked
- 2006-12-22 NZ NZ570162A patent/NZ570162A/en unknown
- 2006-12-22 WO PCT/EP2006/070135 patent/WO2007077162A1/en not_active Ceased
- 2006-12-22 KR KR1020087019159A patent/KR20080083060A/ko not_active Ceased
- 2006-12-22 MY MYPI20082435A patent/MY146362A/en unknown
- 2006-12-22 DK DK06830792.5T patent/DK1971332T3/da active
- 2006-12-28 US US11/617,320 patent/US20070155773A1/en not_active Abandoned
-
2007
- 2007-01-03 AR ARP070100019A patent/AR059126A1/es unknown
- 2007-01-03 TW TW096100183A patent/TW200731976A/zh unknown
-
2008
- 2008-05-22 ZA ZA200804436A patent/ZA200804436B/xx unknown
- 2008-05-28 NO NO20082439A patent/NO20082439L/no not_active Application Discontinuation
- 2008-06-27 EC EC2008008588A patent/ECSP088588A/es unknown
- 2008-07-03 IL IL192602A patent/IL192602A/en active IP Right Grant
-
2011
- 2011-06-07 CY CY20111100543T patent/CY1111534T1/el unknown
-
2015
- 2015-04-24 US US14/695,671 patent/US20150224090A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527220A5 (me) | ||
| HRP20192114T1 (hr) | Deuterirani derivati ivakaftora | |
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| JP2016534088A5 (me) | ||
| WO2012047674A3 (en) | Methods and compositions for disease treatment using inhalation | |
| JP2011162556A5 (me) | ||
| JP2014515351A5 (me) | ||
| PH12014502341A1 (en) | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | |
| MA37577A1 (fr) | 1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques | |
| NZ710726A (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
| MX2009000999A (es) | Derivados de quinuclidina como antagonistas de m3. | |
| RU2010113569A (ru) | Производное бензохинона е3330 в комбинации с химиотерапевтическими агентами для лечения рака и ангиогенеза | |
| HRP20110232T1 (hr) | Antagonisti muskarinskog acetilkolinskog receptora | |
| NO20062569L (no) | Nye krystallinske anhydrider med antikolinergisk effekt | |
| SG11201804449WA (en) | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | |
| NZ705260A (en) | Aerosol pirfenidone and pyridine analog compounds for the treatment of lung disease | |
| ME01205B (me) | Upotreba soli tiotropijuma u liječenju umjerene trajne astme | |
| JOP20190052A1 (ar) | 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز | |
| HRP20191339T1 (hr) | Novi anelirani fenoksiacetamidi | |
| WO2009019598A3 (en) | Inhalation therapy for respiratory disorders | |
| JP2014520874A5 (me) | ||
| RU2013153202A (ru) | Композиции для ингалятора сухого порошка, содержащие умеклидиний | |
| NZ547276A (en) | Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same | |
| EA029678B9 (ru) | Четвертичные соли пиперидиния | |
| MX368036B (es) | Particulas inhalables que comprenden tiotropio e indacaterol. |